Search - tctmd.com

Displaying 1 - 20 of 212

Sort: Relevancy | Date

What Makes MedTech Great—or Not—and Envisioning Its Future

News Conference News TCT 2025

What Makes MedTech Great—or Not—and Envisioning Its Future

November 04, 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

November 03, 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Stent’s Benefits Seen Over Time

News Conference News TCT 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Michael O'Riordan

October 29, 2025

iFR-Guided Immediate PCI Not Superior to Deferred CMR-Guided Strategy in STEMI

News Conference News TCT 2025

iFR-Guided Immediate PCI Not Superior to Deferred CMR-Guided Strategy in STEMI

Yael L. Maxwell

October 28, 2025

PROCTOR: PCI of Failed Bypass Grafts Tops Native-Vessel PCI, With Caveats

News Conference News TCT 2025

PROCTOR: PCI of Failed Bypass Grafts Tops Native-Vessel PCI, With Caveats

October 28, 2025

STRIVE: Low-Dose Alteplase Ineffective in STEMI Patients With Large Thrombus

News Conference News TCT 2025

STRIVE: Low-Dose Alteplase Ineffective in STEMI Patients With Large Thrombus

Michael O'Riordan

October 28, 2025

ENCIRCLE: Good Results With Sapien M3 Transseptal TMVR

News Conference News TCT 2025

ENCIRCLE: Good Results With Sapien M3 Transseptal TMVR

October 27, 2025

Tendyne Safely Reduces MR in Patients With Severe Calcification: SUMMIT-MAC

News Conference News TCT 2025

Tendyne Safely Reduces MR in Patients With Severe Calcification: SUMMIT-MAC

Yael L. Maxwell

October 27, 2025

PREVUE-VALVE Charts the Prevalence of Valve Disease in the United States

News Conference News TCT 2025

PREVUE-VALVE Charts the Prevalence of Valve Disease in the United States

October 27, 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

News Conference News TCT 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Michael O'Riordan

October 26, 2025

Trials Bolster Alternatives to Intravascular Lithotripsy for Calcified Lesions

News Conference News TCT 2025

Trials Bolster Alternatives to Intravascular Lithotripsy for Calcified Lesions

October 26, 2025

TTVR Remains Safe, Effective in Presence of CIED Leads

News Conference News TCT 2025

TTVR Remains Safe, Effective in Presence of CIED Leads

October 25, 2025

What’s Going to Be Hot at TCT 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

Few Patients Under 65 Get TAVI: Those Who Do Are Especially Sick

News Conference News TCT 2024

Few Patients Under 65 Get TAVI: Those Who Do Are Especially Sick

Yael L. Maxwell

November 07, 2024

Co-STAR Hints That Colchicine May Curb Rhythm Disturbances After TAVI

News Conference News TCT 2024

Co-STAR Hints That Colchicine May Curb Rhythm Disturbances After TAVI

Michael O'Riordan

November 06, 2024

After TAVI, Single Antiplatelet Better Than Dual: TRITAVI Registry

News Conference News TCT 2024

After TAVI, Single Antiplatelet Better Than Dual: TRITAVI Registry

Yael L. Maxwell

November 05, 2024

Vascular Closure via Suture/Plug Combo Reduces Complications: ACCESS-TAVI

News Conference News TCT 2024

Vascular Closure via Suture/Plug Combo Reduces Complications: ACCESS-TAVI

November 04, 2024

Embolic Protection Benefits Varied by Geography in PROTECTED TAVR

News Conference News TCT 2024

Embolic Protection Benefits Varied by Geography in PROTECTED TAVR

October 31, 2024

News Conference News TCT 2024

Bleeding After MCS in DanGer Shock: When, Where, and What to Do?

October 31, 2024

TRILUMINATE: More Patient Data Reassure on TEER’s Benefits for Severe TR

News Conference News TCT 2024

TRILUMINATE: More Patient Data Reassure on TEER’s Benefits for Severe TR

Michael O'Riordan

October 29, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.